CN115873018B - Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof - Google Patents
Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof Download PDFInfo
- Publication number
- CN115873018B CN115873018B CN202211448593.9A CN202211448593A CN115873018B CN 115873018 B CN115873018 B CN 115873018B CN 202211448593 A CN202211448593 A CN 202211448593A CN 115873018 B CN115873018 B CN 115873018B
- Authority
- CN
- China
- Prior art keywords
- compound
- ddd
- hpk1
- mmol
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000015556 catabolic process Effects 0.000 title abstract description 16
- 238000006731 degradation reaction Methods 0.000 title abstract description 16
- 108091000080 Phosphotransferase Proteins 0.000 title abstract description 12
- 102000020233 phosphotransferase Human genes 0.000 title abstract description 12
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 title abstract description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 title abstract description 5
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title abstract description 4
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 claims abstract description 55
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims description 126
- 150000003839 salts Chemical class 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 108010026668 snake venom protein C activator Proteins 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 238000011865 proteolysis targeting chimera technique Methods 0.000 abstract description 16
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 abstract description 16
- 239000003112 inhibitor Substances 0.000 abstract description 12
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 150000003384 small molecules Chemical class 0.000 abstract description 6
- 230000005975 antitumor immune response Effects 0.000 abstract description 5
- 239000012636 effector Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 description 75
- 230000015572 biosynthetic process Effects 0.000 description 57
- 238000003786 synthesis reaction Methods 0.000 description 57
- 238000006243 chemical reaction Methods 0.000 description 38
- 239000007858 starting material Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 31
- 238000005481 NMR spectroscopy Methods 0.000 description 29
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 238000010189 synthetic method Methods 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 21
- 239000000203 mixture Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- -1 pyridomorpholinyl Chemical group 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000001035 drying Methods 0.000 description 15
- 239000002994 raw material Substances 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 13
- 239000002207 metabolite Substances 0.000 description 13
- 238000000967 suction filtration Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- 102100028193 Mitogen-activated protein kinase kinase kinase kinase 3 Human genes 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 101710144521 Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 2
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 101150048236 hpk-1 gene Proteins 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 1
- RZYXBJMVAFMMLQ-UHFFFAOYSA-N 2-(2-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC=C1F RZYXBJMVAFMMLQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- IGTYEXMPMYGLTR-OAQYLSRUSA-N CC1=CC(C2=NC(OC3=CN(C4CCN(C)CC4)N=C3)=C(N)N=C2)=CC(C)=C1C(NCCN(CC1)C[C@@H]1F)=O Chemical compound CC1=CC(C2=NC(OC3=CN(C4CCN(C)CC4)N=C3)=C(N)N=C2)=CC(C)=C1C(NCCN(CC1)C[C@@H]1F)=O IGTYEXMPMYGLTR-OAQYLSRUSA-N 0.000 description 1
- 102000015367 CRBN Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229920002430 Fibre-reinforced plastic Polymers 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940125962 HPK1 kinase inhibitor Drugs 0.000 description 1
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 description 1
- 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 101001059989 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 description 1
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 1
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100026287 Misshapen-like kinase 1 Human genes 0.000 description 1
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 1
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 1
- 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229940126655 NDI-034858 Drugs 0.000 description 1
- 241000290929 Nimbus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- KOAOUMQUUZNRLL-UHFFFAOYSA-N dec-9-yn-1-ol Chemical compound OCCCCCCCCC#C KOAOUMQUUZNRLL-UHFFFAOYSA-N 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000011151 fibre-reinforced plastic Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof. The invention utilizes the advantage that PROTAC can realize selectivity which is difficult to realize by small molecules, and develops a class of benzimidazole and benzotriazine HPK1 PROTAC degradation agents. The PROTAC can degrade HPK1 protein with high efficiency and high selectivity, and has no degradation activity on other proteins in the same family. Compared with the HPK1 small molecule inhibitor, the anti-tumor immune response of the T cells can be stimulated more effectively, the effector cell factor is released, and the anti-tumor activity is stronger.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof.
Background
Immunotherapy thoroughly changes the treatment mode of cancer and brings new hopes for patients. In particular, immune checkpoint inhibitors against the PD-1 and CTLA-4 pathways show significant clinical effects, but they are only effective against specific patient populations, specific types of tumors, with low tumor response rates (-30%), and most patients do not show long lasting symptomatic relief, develop resistance after a period of administration. Therefore, a new tumor immunotherapy target is needed to be discovered, the clinical effect of immune check points is improved, and the method has important significance for application and popularization of tumor immunotherapy.
Hematopoietic progenitor kinase 1 (HPK 1, MAP4K 1) is one of the members of the MAP4K family, a Ste20 silk/threonine protein kinase. There are 5 members of the MAP4K family, including MAP4K2, MAP4K3, MAP4K4, MAP4K5 and MAP4K6, in addition to HPK 1. HPK1 is expressed primarily in hematopoietic cells such as T cells, B cells, neutrophils, dendritic Cells (DCs), natural Killer (NK) cells, and macrophages. Numerous studies have shown that HPK1 is a negative regulator of T cell receptors and B cell receptors. After TCR activation, HPK1 in the cytoplasm is recruited to the plasma membrane, where its amino acid residues Y381, S171 and T165 are phosphorylated, resulting in a fully kinase-activated HPK1 kinase. The activated HPK1 phosphorylates the amino acid residue S376 of the linker protein SLP76, provides a binding site for the negative regulatory factor 14-3-3, promotes the degradation of SLP76 by a proteasome, and finally breaks down the stability of the TCR signal complex, thereby blocking the kinase signal pathway downstream for promoting T cell activation and proliferation. In addition to TCR signaling, HPK1 negatively regulates T cell signaling through prostaglandin E2 (PGE 2) receptors. In addition, HPK1 can also transmit immunosuppressive signals in B cells, NK cells, and dendritic cells under stimulation by growth factors, stress, inflammatory factors, and differentiation factors, among others. In addition, a recent study has shown that kinase activity of HPK1 inhibits immune function in a variety of cells, including CD4 + T cells, CD8 + T cells, NK cells and dendritic cells, and demonstrate that inhibition of the kinase activity of HPK1 is sufficient to induce an anti-tumor immune response. In addition, inhibiting the activity of HPK1 kinase can further promote T cell effector function and obviously increase the therapeutic effect of PD-L1 monoclonal antibody. HPK1 gene deletion, HPK1 inhibitor or HPK1 protac degradation agent can enhance CAR-T cell-based immunotherapy, in various preclinical hematologies andthe solid tumor mouse model shows better anti-tumor activity. Notably, neither the HPK1 gene knockout nor the inactivated kinase knockout mice showed a lethal inflammatory response, but these were significant in the absence of some other immune negative regulators, such as CTLA-4 and Cbl-b, indicating a higher safety profile for HPK1 inhibitors. In view of the above, HPK1 is a new target of tumor immunotherapy that is potentially effective, and research and development of HPK1 inhibitors are of great importance for improving the key problems currently faced by tumor immunotherapy.
Over a decade ago, developers discovered that HPK1 could be a potential tumor immunotherapy target, HPK1 inhibitors were favored by various pharmaceutical companies and scientific institutions, various structures of HPK1 inhibitors were reported, and it was not completely counted that 4 HPK1 inhibitors were currently in early clinical research stages, including CFI-402411 of Treadwell Therapeutics, BGB-15025 of baji, and NDI-101150 of PRJ1-3024 and Nimbus Therapeutics of zhuhai. At present, their structure has not been disclosed. Although a variety of HPK1 inhibitors have been reported, no related drugs are currently marketed. The challenges faced in the development of HPK1 inhibitors are mainly the difference in HPK1 family member functions, but the structural homology is very high, and the difficulty in designing highly selective inhibitors is great.
Compared with traditional medicines, PROTAC has the remarkable advantages that: the application range is wider, the activity is higher, and the target can be targeted to a target point which is not patent medicine; the selectivity, activity and safety are improved; overcomes drug resistance of tumor drugs, etc. The PROTAC can realize the selectivity which is difficult to realize by small molecules on certain targets, so that the development of the HPK1 PROTAC molecules is expected to solve the problems of low selectivity, incapacity of dose dependence of drug effect and the like of HPK1 inhibitors, and the HPK1 PROTAC molecules are rarely reported at present. Therefore, the research and development of the HPK1 PROTAC molecule are urgent, and the HPK1 PROTAC molecule has important scientific significance and development value.
Disclosure of Invention
Aiming at the problem of low selectivity of the HPK1 small molecule inhibitor, the invention utilizes the advantage of the selectivity which is difficult to realize by the small molecule of PROTAC, develops the PROTAC molecule of the targeted HPK1, and provides a benzimidazole and benzotriazine HPK1 PROTAC degradation agent. The PROTAC can degrade HPK1 protein with high efficiency and high selectivity, and has no degradation activity on other proteins in the same family. Compared with the HPK1 small molecule inhibitor, the anti-tumor immune response of the T cells can be stimulated more effectively, the effector cell factor is released, and the anti-tumor activity is stronger.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a compound of formula I, or a pharmaceutically acceptable salt, isomer, metabolite, prodrug, solvate or hydrate thereof,
in formula I:
R 1 hydrogen, halogen or cyano;
R 2 is unsubstituted or R 2-1 Substituted C 6-10 Aryl, unsubstituted or R 2-2 The substituted hetero atom is selected from one or more of ' N, O or S ', and the hetero atom number is 1-3 ' 5-10 membered heteroaryl;
R 2-1 is halogen, C 1-6 Alkoxy, unsubstituted or R 2-1-1 Substituted C 1-6 An alkyl group;
R 2-1-1 is hydroxy or halogen;
R 2-2 is halogen, amino or C 1-6 An alkyl group;
R 3 is hydrogen or amino;
q is N or C;
a is“/>"terminal" means attached to NH and "- - -" terminal means attached to L;
b is E3 ubiquitin ligase ligand CRBN or VHL;
l is“/>"terminal" means attached to A and "- -" terminal means attached to B;
m is an integer between 0 and 5;
n is an integer between 0 and 10;
o is an integer between 1 and 5;
x is C, O, NH,“/>The "terminal" means attached to L and the "- - -" terminal means attached to B.
In some embodiments, B isOr->Y is hydrogen, deuterium, fluorine or chlorine; w is CH 2 Or carbonyl; g is hydrogen or methyl; z is hydrogen or methyl.
In some embodiments, B is
In some embodiments, R 2 Is unsubstituted or R 2-1 Substituted phenyl, unsubstituted or R 2-2 Substituted pyridinyl, unsubstituted or R 2-2 Substituted pyridomorpholinyl.
In some embodiments, R 2 Is that
In some embodiments, a compound of formula I, or a pharmaceutically acceptable salt, isomer, metabolite, prodrug, solvate or hydrate thereof, is of the formula:
wherein A, L and B are as defined above.
In some embodiments, the compound of formula I is selected from compounds of any one of the following structures:
the use of a compound of formula I, or a pharmaceutically acceptable salt, isomer, metabolite, prodrug, solvate or hydrate thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of cancer.
In some embodiments, the cancer is one or more of bone cancer, lung cancer, stomach cancer, colon cancer, membranous adenocarcinoma, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cancer of the shoulders, cervical cancer, cancer of the kidneys, head and neck cancer, thyroid cancer, esophageal cancer, lymphatic cancer, leukemia, or skin cancer.
A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt, isomer, metabolite, prodrug, solvate or hydrate thereof, and a pharmaceutically acceptable carrier or adjuvant.
In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt, isomer, metabolite, prodrug, solvate or hydrate thereof, is used in the pharmaceutical composition in an amount effective for treatment.
The invention provides an application of a pharmaceutical composition in preparing a medicament for treating and/or preventing cancer.
In some embodiments, the cancer is one or more of bone cancer, lung cancer, stomach cancer, colon cancer, membranous adenocarcinoma, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cancer of the shoulders, cervical cancer, cancer of the kidneys, head and neck cancer, thyroid cancer, esophageal cancer, lymphatic cancer, leukemia, or skin cancer.
The pharmaceutical excipients can be those which are widely used in the field of pharmaceutical production. Adjuvants are used primarily to provide a safe, stable and functional pharmaceutical composition, and may also provide means for allowing the subject to dissolve at a desired rate after administration, or for promoting effective absorption of the active ingredient after administration of the composition. The pharmaceutical excipients may be inert fillers or provide a function such as stabilizing the overall pH of the composition or preventing degradation of the active ingredients of the composition. The pharmaceutical excipients can comprise one or more of the following excipients: binders, suspending agents, emulsifiers, diluents, fillers, granulating agents, sizing agents, disintegrants, lubricants, anti-adherents, glidants, wetting agents, gelling agents, absorption retarders, dissolution inhibitors, enhancing agents, adsorbents, buffering agents, chelating agents, preservatives, colorants, flavoring agents, and sweeteners.
The pharmaceutical compositions of the present invention may be prepared in accordance with the disclosure using any method known to those of skill in the art. For example, conventional mixing, dissolving, granulating, emulsifying, levigating, encapsulating, entrapping or lyophilizing processes.
The pharmaceutical compositions of the present invention may be administered in any form, including injection (intravenous), mucosal, oral (solid and liquid formulations), inhalation, ocular, rectal, topical or parenteral (infusion, injection, implantation, subcutaneous, intravenous, intra-arterial, intramuscular). The pharmaceutical compositions of the invention may also be in controlled or delayed release dosage forms (e.g., liposomes or microspheres). Examples of solid oral formulations include, but are not limited to, powders, capsules, caplets, soft capsules, and tablets. Examples of liquid formulations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs and solutions. Examples of topical formulations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops or serum formulations. Examples of formulations for parenteral administration include, but are not limited to, solutions for injection, dry formulations which may be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Examples of other suitable formulations of the pharmaceutical composition include, but are not limited to, eye drops and other ophthalmic formulations; aerosol: such as nasal sprays or inhalants; a liquid dosage form suitable for parenteral administration; suppositories and lozenges.
The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention prepared from the compounds of the present invention which have the specified substituents found herein with relatively non-toxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts may be obtained by contacting the free form of such compounds with a sufficient amount of base in pure solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salts or similar salts. When the compounds of the present invention contain relatively basic functional groups, the acid addition salts may be obtained by contacting the free form of such compounds with a sufficient amount of acid in pure solution or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid (forming carbonates or bicarbonates), phosphoric acid (forming phosphates, monohydrogenphosphates, dihydrogenphosphates, sulfuric acid (forming sulfates or bisulphates), hydroiodic acid, phosphorous acid, and the like, and organic acid salts including, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, and the like, salts of amino acids (such as arginine and the like), and salts of organic acids such as glucuronic acid.
The "pharmaceutically acceptable salts" of the present invention can be synthesized from the parent compound containing an acid or base by conventional chemical methods. In general, the preparation of such salts is as follows: prepared via reaction of these compounds in free acid or base form with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of both. Generally, nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
The term "isomer" refers to compounds of the same chemical formula but having different arrangements of atoms.
The term "metabolite" refers to a pharmaceutically active product of a compound of formula I or a salt thereof produced by in vivo metabolism. Such products may result from, for example, oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, glucuronidation, enzymatic cleavage, etc. of the administered compound. Accordingly, the present invention includes metabolites of the compounds of the present invention, including compounds produced by a method of contacting a compound of the present invention with a mammal for a period of time sufficient to obtain the metabolites thereof.
Identification of metabolites typically occurs by preparing a radiolabeled isotope of a compound of the invention, parenterally administering it to an animal, such as a rat, mouse, guinea pig, monkey, or human, in a detectable dose (e.g., greater than about 0.5 mg/kg), allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion product from urine, blood, or other biological samples. These products are easy to isolate because they are labeled (others are isolated by using antibodies that are capable of binding to epitopes present in the metabolite). The metabolite structures are determined in a conventional manner, for example by MS, LC/MS or NMR analysis. In general, the analysis of metabolites is performed in the same manner as conventional drug metabolism studies known to those skilled in the art. So long as it takes the place ofThe metabolite products are not otherwise undetectable in vivo, or they may be used in assays for the therapeutic dosing of the compounds of the invention. The compounds of the present invention may contain non-natural proportions of atomic isotopes on one or more of the atoms comprising the compounds. For example, compounds can be labeled with radioisotopes, such as tritium @, for example 3 H) Iodine-125% 125 I) Or C-14% 14 C) A. The invention relates to a method for producing a fibre-reinforced plastic composite All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
In addition to salt forms, the compounds provided herein exist in prodrug forms. Prodrugs of the compounds described herein readily undergo chemical changes under physiological conditions to convert to the compounds of the invention. Any compound that can be converted in vivo to provide a biologically active substance (i.e., a compound of formula I) is a prodrug within the scope and spirit of the invention. For example, compounds containing a carboxyl group can form a physiologically hydrolyzable ester that acts as a prodrug by hydrolyzing in vivo to give the compound of formula I itself. The prodrugs are preferably administered orally, as hydrolysis occurs in many cases primarily under the influence of digestive enzymes. Parenteral administration may be used when the ester itself is active or hydrolysis occurs in the blood.
As will be appreciated by those skilled in the art, the present application describes "as used in the structural formula of a group" in accordance with convention used in the art ""and">"means that the corresponding group is attached to other fragments, groups in the compound of formula I through this site.
"substitution" in the present invention may be one or more, and when there are plural "substitution", the "substitution" may be the same or different.
The term "plurality" refers to 2,3, 4, or 5.
The term "halogen" refers to fluorine, chlorine, bromine or iodine.
The term "alkyl" refers to a straight or branched chain alkyl group having the indicated number of carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl and the like.
The term "aryl" refers to an aromatic group having the indicated number of carbon atoms, preferably a monocyclic, bicyclic or tricyclic aromatic group, and when bicyclic or tricyclic, each ring satisfies the shock rule. C of the invention 6-10 Aryl refers to an aromatic group containing 6 to 10 carbon atoms, such as phenyl or naphthyl.
The term "heteroaryl" refers to an aromatic group containing heteroatoms, preferably an aromatic 5-6 membered monocyclic, aromatic 9-10 membered bicyclic or 9-10 membered heteroaromatic saturated heterocycle containing 1,2 or 3 atoms independently selected from nitrogen, oxygen and sulfur. The 5-to 6-membered monocyclic ring includes, but is not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2, 3-triazolyl, 1,2, 4-triazolyl, furazanyl, 1,2, 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1,2, 5-oxadiazolyl, 1,3, 4-oxadiazolyl, thiadiazolyl, dithiazolyl, tetrazolyl, pyridyl, pyranyl, thiopyranyl, diazinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxinyl, dithiinyl, 1,2, 3-triazinyl, 1,2, 4-triazinyl, 1,3, 5-triazinyl or tetrazinyl. The 9-to 10-membered bicyclic ring includes, but is not limited to, benzimidazolyl, indolyl, indazolyl, benzofuranyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisozolyl, quinolinyl, isoquinolinyl, benzomorpholinyl, benzopiperidinyl, pyrazolomorpholinyl.
The above preferred conditions can be arbitrarily combined on the basis of not deviating from the common knowledge in the art, and thus, each preferred embodiment of the present invention can be obtained.
The reagents and materials used in the present invention are commercially available.
The invention has the advantages that:
(1) The HPK1 PROTAC molecule provided by the invention can efficiently and selectively degrade HPK1 protein, and has no degradation activity on proteins such as GLK in the same family.
(2) The HPK1 PROTAC molecules provided by the invention can more effectively stimulate the anti-tumor immune response of T cells
(3) The HPK1 PROTAC molecule provided by the invention has good therapeutic effect on cancers.
Detailed Description
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
EXAMPLE 1 Synthesis of Compound 4
a) 2, 6-tetramethylpiperidine (L87 g,1.33 mol) was dissolved in THF (1.4L), cooled to-78℃and a 2.5M n-BuLi/THF solution (400 mL,1.00 mol) was slowly added dropwise thereto, stirring was completed for 30 minutes, compound 1 (140 g,663 mmol) was dissolved in THF (1.12L), then the reaction solution was slowly added dropwise thereto, stirring was carried out at-78℃for 1 hour, and then ethyl formate (59 g,796 mol) was dissolved in THF (280 mL), and then the reaction solution was added dropwise thereto and stirring was carried out for 1 hour. After the reaction is completed, saturated NH is used 4 Cl solution (2L) was quenched and extracted with ethyl acetate (1 L×3), the combined organic layers were washed with saturated NaCl solution, dried over anhydrous Na 2 SO 4 Drying, suction filtration for salt removal, and column chromatography purification by vacuum concentration gave intermediate 2 (42 g, 27%). MS (ESI, M/z): 239 (M) + +1)。
b) Intermediate 2 (50 g,209 mmol), DIPEA (55 g,430 mmol), HNPMB 2 (63 g,240 mmol) was dissolved in 1, 4-dioxane (500 mL) and warmed to 100deg.C and stirred for 6h. The reaction solution was concentrated and purified by column chromatography to give intermediate 3 (90 g, 90%). MS (ESI, M/z): 476 (M) + +1)。
c) Intermediate 3 (90 g,189 mmol), cs 2 CO 3 (122 g,374 mmol) guanidine carbonate (44 g,242 mmol) was dissolved inIn DMA (360 mL), the reaction was stirred at 150℃for 30min. The reaction solution was cooled to room temperature, diluted with water and extracted with ethyl acetate (200 mL. Times.3), the combined organic layers were washed with saturated NaCl solution, and dried over anhydrous Na 2 SO 4 Drying, suction filtration for salt removal, and column chromatography purification by vacuum concentration gave intermediate 4 (31 g, 33%). MS (ESI, M/z): 497 (M) + +1)。
EXAMPLE 2 Synthesis of Compound 6
Guanidine carbonate (2.34 g,13.0 mmol) and DIPEA (4.42 mL,26.0 mmol) were dissolved in NMP (20 mL), heated to 160℃and a solution of Compound 5 (4.59 g,10.0 mmol) in NMP (5 mL) was slowly added to the hot reaction mixture. The reaction was stirred at 160℃for 2h, cooled to below 100℃and an ice-water mixture (100 mL) was added. The mixture was stirred at room temperature for 30min. The mixture was filtered and washed with water (20 mL) and ethanol (20 mL), and the filter cake was stirred with ethanol (20 mL) for 1h and then filtered again. The solid was washed with ethanol (20 mL), ethanol/toluene mixture (20 mL, 1:1) and toluene (20 mL) and the solid was dried to give product 6 (1.91 g, 40%). MS (ESI, M/z): 479 (M) + +1)。
EXAMPLE 3 Synthesis of Compound 8
Raw material 7 (2.17 g,5.8 mmol), guanidine hydrochloride (1.11 g,11.6 mmol), potassium tert-butoxide (5.2 g,46.4 mmol) were dissolved in THF (40 mL), refluxed for 2h, diluted with water after the reaction was complete, extracted with ethyl acetate (20 mL. Times.3), the combined organic layers were washed with saturated NaCl solution, and dried over anhydrous Na 2 SO 4 Drying, suction filtration of salt, concentration under reduced pressure gave intermediate 8 (672 mg, 29%) which was purified by column chromatography. MS (ESI, M/z): 396 (M) + +1)。
EXAMPLE 4 Synthesis of Compound 10
To a 30mL tube was added the starting material (268 mg,2.7 mmol), guanidine carbonate (4816 mg,2.7 mmol) was dissolved in DMA (13 mL), reacted at 100℃for 4h, the reaction solution was cooled and poured into 50mL of ice, stirred for 15min, and suction filtered to obtain an intermediate (553 mg, 91%). MS (ESI, M/z): 224 (M) + +1)。
Example 5 Synthesis of intermediates 13 and 15
a) Under argon, intermediate 4 (200 mg,0.4 mmol), 2-fluorophenylboronic acid pinacol ester (133 mg,0.6 mmol), pd (dppf) Cl 2 (29 mg,0.04 mmol) and Na 2 CO 3 (85 mg,0.8 mmol) was dissolved in 1, 4-dioxane (2 mL) and water (0.4 mL) and stirred at 100deg.C overnight. After completion of the reaction, the reaction mixture was cooled to room temperature, diluted with water, extracted with dichloromethane (10 mL. Times.3), the combined organic layers were washed with saturated NaCl solution, and dried over anhydrous Na 2 SO 4 Drying, suction filtration of salt, concentration under reduced pressure, and purification by column chromatography gave intermediate 11 (63 mg, 31%). MS (ESI, M/z): 513 (M) + +1)。
b) Under argon, intermediate 11 (313 mg,1 mmol), 2-trifluoro-1- (5-methoxy-7- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -3, 4-dihydroisoquinolin-2 (1H) -yl) ethan-1-one (423 mg,1.1 mmol), K 3 PO 4 (316mg,1.5mmol)、Pd 2 (dba) 3 (92 mg,0.1 mmol), t-BuBrettPhos (96 mg,0.2 mmol), toluene (4 mL) and water (0.8 mL), and after completion of the reaction overnight at 110℃the filtrate was filtered off with suction and concentrated under reduced pressure and purified by column chromatography to give intermediate 12 (284 mg, 37%). MS (ESI, M/z): 770 (M) + +1)。
c) Intermediate 12 (6754 mg,1 mmol) was dissolved in methanol and K was added 2 CO 3 (276 mg,2 mmol) at room temperature for 2h, and after completion of the reaction, K was removed by suction filtration 2 CO 3 Spin-drying afforded intermediate 13 (620 mg, 92%). MS (ESI, M/z): 674 (M) + +1)。
d) Intermediate 13 (6754 mg,1 mmol) was dissolved in acetonitrile, ethyl bromoacetate (200 mg,1.2 mmol) was added, DIPEA reacted at room temperature for 2h, after completion of the reaction cooled to room temperature, ethyl acetate extracted (10 mL. Times.3), the combined organic layers were washed with saturated NaCl solution, and dried over anhydrous Na 2 SO 4 Drying, suction filtration for salt removal, and column chromatography purification by vacuum concentration gave intermediate 14 (292 mg, 85%). MS (ESI, M/z): 743.3 (M) + +1)。
e) Intermediate 14 (743 mg,1 mmol) was dissolved in tetrahydrofuran, 2M aqueous NaOH (1 mL) was added and reacted at room temperature for 2h, after completion of the reaction, pH was adjusted to acidity with 2M HCl, and the filter cake was obtained by suction filtration and dried under vacuum to obtain intermediate 15 (661mg, 92%). MS (ESI, M/z): 715 (M) + +1)。
Example 6 Synthesis of intermediates 18 and 20
The synthesis is described in reference to the synthesis method of example 5, and only the corresponding raw materials need to be replaced. Intermediate 18: MS (ESI, M/z): 715 (M) + +1). Intermediate 20: MS (ESI, M/z): 715 (M) + +1)。
Example 7 Synthesis of intermediates 22 and 24
The synthesis is described in reference to the synthesis method of example 5, and only the corresponding raw materials need to be replaced. Intermediate 22: MS (ESI, M/z): 715 (M) + +1). Intermediate 24: MS (ESI, M/z): 715 (M) + +1)。
Example 8 Synthesis of intermediate 26
The synthesis is described in reference to the synthesis method of example 5, and only the corresponding raw materials need to be replaced. Intermediate 26: MS (ESI, M/z): 715 (M) + +1)。
Example 9 Synthesis of intermediate 31
The synthesis is described in reference to the synthesis method of example 5, and only the corresponding raw materials need to be replaced. Intermediate 26: MS (ESI, M/z): 715 (M) + +1)。
Example 10 Synthesis of intermediates 34 and 36
The synthesis is described in reference to the synthesis method of example 5, and only the corresponding raw materials need to be replaced. Intermediate 26: MS (ESI, M/z): 715 (M) + +1)。
Example 11 Synthesis of intermediates 50, 52 and 53
a) Raw material 47 (2.0 g,7.25 mmol) was dissolved in DMF (10 mL), tert-butyl glycinate (1.14 g,8.69 mmol) and DIPEA (2.1 g,9.43 mmol) were added to the reaction system, reacted at 90℃for 5h, cooled to room temperature after completion of the reaction, diluted with water, extracted with dichloromethane (10 mL. Times.3), the organic phase was combined, washed with saturated NaCl solution, and anhydrous Na 2 SO 4 Drying, suction filtration to remove salt, and concentration under reduced pressure gave intermediate 48a (1.58 g, 56%) which was purified by column chromatography. MS (ESI, M/z): 410 (M) + +1). The intermediates 48b,51a-b,53a-e can be obtained by the same preparation method by only replacing the corresponding raw materials.
b) Intermediate 48a (387.4 mg,1 mmol) was dissolved in dioxymethane (2 mL), trifluoroacetic acid (148. Mu.L) was added, and reacted at 25℃for 8h, followed by direct spin-drying to give intermediate 49a (2910 mg, 88%). MS (ESI, M/z): 332 (M) + +1). The intermediates 49b,35a-b were prepared in the same manner, except that the corresponding starting materials were replaced.
c) Raw material 49a (331 mg,1 mmol) was dissolved in DMF, added5-Bromopentanamine (200 mg,1.2 mmol) and DIPEA (3838 mg,3 mmol) were added, reacted at room temperature for 2h, cooled to room temperature after completion of the reaction, diluted with water, extracted with dichloromethane (10 mL. Times.3), the organic phases were combined, washed with saturated NaCl solution, and dried Na 2 SO 4 Drying, suction filtration of salt, concentration under reduced pressure gave intermediate 50 (249 mg, 50%) which was purified by column chromatography. MS (ESI, M/z): 479 (M) + +1)。
d) Intermediate 51a (1 mmol) was dissolved in a solution of dichloromethane (1 mmol/5 mL) and methanol (1 mmol/1 mL), a solution of 4 MHz Cl in dioxane (0.5 mL) was added at 0deg.C, the reaction was allowed to proceed at room temperature for 4h, after completion of the TLC monitoring reaction, the reaction solution was dried by spin-drying, slurried with isopropyl ether, and suction filtered to obtain intermediate. MS (ESI, M/z): 317 (M) + +1). Intermediates 52a and 52b were prepared in the same manner, except that the corresponding starting materials were replaced.
Example 12 Synthesis of intermediate 55
Synthesis of intermediate 55 a: a) Bromoacetic acid (139 mg,1 mmol) was added to the reaction flask, and thionyl chloride (1 mL) was added thereto, and the reaction was stirred at 80℃for 5 hours. The reaction is cooled to room temperature completely, dried tetrahydrofuran is added for dissolution after spin drying, then raw material 54 (273 mg,1 mmol) is added for reaction at 50 ℃, after TLC monitoring the reaction is complete, the crude product of intermediate 55a can be obtained after cooling and suction filtration. MS (ESI, M/z): 394 (M) + +1)。
Synthesis of intermediate 55 b: intermediate 55b was prepared in the same manner, except that the corresponding starting materials were replaced. MS (ESI, M/z): 450 (M) + +1)。
Example 13 Synthesis of intermediates 58, 60 and 61
Synthesis of intermediate 58: a) Raw material 56 (1.57 g,5.71 mmol) was dissolved in DMF (57 mL) and K was added 2 CO 3 (1.19 g,8.58 mmol) and tert-butyl bromo-tetrapolyethylene glycol-propionate (2.2 g, 5).71 mmol), stirring at room temperature, reacting for 2h, quenching with water after the reaction is completed, extracting with dichloromethane (30 mL. Times.3), combining organic phases, washing with saturated NaCl solution, and anhydrous Na 2 SO 4 Drying, suction filtration to remove salt, concentration under reduced pressure, and purification by column chromatography gave intermediate 57 (3.07 g, 93%). MS (ESI, M/z): 579 (M) + +1). b) Raw material 57 (576 mg,1 mmol) was dissolved in DCM (5 mL), TFA (2 mmol) was added dropwise at 0deg.C, the reaction was stirred at room temperature for 3h and concentrated under reduced pressure to give crude intermediate 58 (470 mg, 90%). MS (ESI, M/z): 523 (M) + +1)。
Synthesis of intermediate 60: synthesis reference synthesis of intermediate 58 requires only the replacement of the corresponding starting materials. MS (ESI, M/z): 360 (M) + +1)。
Synthesis of intermediate 61: synthesis reference synthesis of intermediate 58 requires only the replacement of the corresponding starting materials. MS (ESI, M/z): 437 (M) + +1)。
Example 14 Synthesis of intermediates 64, 67 and 71
a) Under argon, starting material 62 (323 mg,1 mmol), 9-decyn-1-ol (185 mg,1.2 mmol), pd (PPh) 3 ) 2 Cl 2 (10 mol%), cuI (10 mol%) and DIPEA (1.29 g,10 mmol) were dissolved in THF and stirred at room temperature for 10h, quenched with water after completion of the reaction, extracted with ethyl acetate (10 mL. Times.3), the organic phases combined, washed with saturated NaCl solution, anhydrous Na 2 SO 4 Drying, suction filtration of salt, concentration under reduced pressure gave intermediate 63 (309 mg, 78%) which was purified by column chromatography. MS (ESI, M/z): 397 (M) + +1). Intermediates 66 and 69 were prepared in the same manner, except that the corresponding starting materials were replaced.
b) Raw material 63 (397 mg,1 mmol) was dissolved in acetone, and 2M Jones reagent (1 mL) was added dropwise at 0deg.C. The reaction was stirred at room temperature for 30min, monitored by TLC for completion, extracted with ethyl acetate, anhydrous Na 2 SO 4 Dried and concentrated under reduced pressure to give crude intermediate 64 (229 mg, 56%). MS (ESI, M/z): 411 (M) + +1). The intermediate is prepared by the same method only by replacing corresponding raw materials67 and 70.
c) Intermediate 70 (268 mg,1 mmol) was dissolved in THF (5 mL), 10% Pd/C (37 mg) was added and the mixture was purged three times with hydrogen balloon. The reaction was stirred at room temperature for 12h, filtered through celite, and the filtrate was concentrated under reduced pressure to give crude intermediate 71 (167 mg, 45%). MS (ESI, M/z): 373 (M) + +1)。
Example 15 Synthesis of intermediates 74 and 75
Synthesis of intermediate 74: a) Raw material 72 (444 mg,1 mmol), N, N-bis-Boc-4-aminobutyric acid (803 mg,1.2 mmol), HATU (560 mg,1.5 mmol) and DIPEA (3838 mg,3 mmol) were dissolved in THF and stirred at room temperature for 2h, ethyl acetate extraction after completion of the reaction, anhydrous Na 2 SO 4 Dried, concentrated under reduced pressure and purified by column chromatography to give intermediate 73 (693 mg, 95%). MS (ESI, M/z): 730 (M) + +1). b) Intermediate 73 (730 mg,1 mmol) was dissolved in dichloromethane (1 mmol/5 mL) and methanol (1 mmol/1 mL), a solution of 4 MHz dioxane (0.5 mL) was added at 0deg.C, the reaction was allowed to proceed at room temperature for 4h, after completion of TLC monitoring the reaction, the reaction mixture was spun dry, slurried with isopropyl ether, and suction filtered to give intermediate 74 (330 mg, 92%). MS (ESI, M/z): 530 (M) + +1)。
Synthesis of intermediate 75: the synthesis reference intermediate 74 is synthesized in the synthesis method step a, and only the corresponding raw materials need to be replaced. MS (ESI, M/z): 635 (M) + +1).
EXAMPLE 16 Synthesis of Compound S1
a) Intermediate 18 (798 mg,1 mmol), intermediate 49a (390 mg,1.2 mmol), HATU (642 mg,1.5 mmol) and DIPEA (3838 mg,3 mmol) were dissolved in THF and reacted at room temperature with stirring for 2h, quenched with water after completion of the reaction, extracted with dichloromethane (10 mL. Times.3), the combined organic phases were washed with saturated NaCl solution, anhydrous Na 2 SO 4 Drying, suction filtering to remove salt, concentrating under reduced pressureColumn chromatography purification yielded intermediate 76 (777 mg, 70%). MS (ESI, M/z): 1129 (M) + +1)。
b) Intermediate 75 (1111 mg,1 mmol) was dissolved in dichloromethane (5 mL), TFA (5 mL) was added dropwise, and the mixture was stirred at room temperature for 2h, after completion of the reaction, concentrated under reduced pressure, and HPLC was performed to obtain Compound S1.
S1: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.41(s,1H),8.70(d,J=1.4Hz,1H),8.20(d,J=1.4Hz,1H),8.05(s,1H),7.58–7.53(m,2H),7.48(t,J=7.8Hz,1H),7.41(d,J=2.3Hz,1H),7.11(ddd,J=12.1,7.8,1.1Hz,1H),6.00(t,J=5.1Hz,1H),5.72(t,J=3.7Hz,1H),5.55(d,J=7.0Hz,1H),5.45(d,J=7.0Hz,1H),5.27(t,J=5.9Hz,1H),4.55(p,J=5.7Hz,1H),4.32(ddd,J=5.2,4.5,0.8Hz,2H),4.23(dd,J=16.8,5.1Hz,1H),4.16(dd,J=16.9,5.1Hz,1H),3.77(ddd,J=11.9,7.9,5.6Hz,2H),3.71–3.57(m,2H),3.43(ddd,J=11.9,7.9,5.6Hz,2H),2.68–2.51(m,2H),2.42(s,3H),2.19–2.03(m,2H),1.98(ddt,J=11.2,7.9,5.6Hz,2H),1.84(ddt,J=11.2,7.9,5.6Hz,2H).CMS(ESI,m/z):789(M + +1).
EXAMPLE 17 Synthesis of Compound S2
a) Intermediate 18 (798 mg,1 mmol), intermediate 55a (473 mg,1.2 mmol) and K 2 CO 3 (258 mg,2 mmol) was dissolved in acetonitrile, stirred at 80℃for 6h, quenched with water after completion of the reaction, extracted with ethyl acetate (10 mL. Times.3), the organic phases were combined, washed with saturated NaCl solution, and dried over anhydrous Na 2 SO 4 Drying, suction filtration of salt, concentration under reduced pressure, and purification by column chromatography gave intermediate 77a (777 mg, 70%). Intermediate 77b can be obtained by simply replacing the corresponding reaction substrate. MS (ESI, M/z): 1129 (M) + +1)。
b) Compound S2 was prepared according to step b of example 16.
S2: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.42(s,1H),8.71(d,J=1.4Hz,1H),8.20(d,J=1.4Hz,1H),8.03–7.95(m,2H),7.69–7.61(m,2H),7.59(d,J=2.2Hz,1H),7.47(dd,J=7.9,1.1Hz,1H),7.40(d,J=2.3Hz,1H),5.72(t,J=3.7Hz,1H),5.55(d,J=7.0Hz,1H),5.45(d,J=7.0Hz,1H),5.12(t,J=5.9Hz,1H),4.37–4.27(m,3H),3.65(ddd,J=5.2,4.4,3.7Hz,2H),3.19(d,J=13.2Hz,1H),3.01–2.90(m,3H),2.64(ddd,J=15.2,8.6,6.4Hz,1H),2.55–2.45(m,4H),2.38(s,3H),2.24–1.98(m,4H),1.88(ddt,J=11.2,7.9,5.6Hz,2H).MS(ESI,m/z):789(M + +1).
EXAMPLE 18 Synthesis of Compound S3
Synthetic method referring to example 16, compound S3 can be prepared by simply replacing the corresponding starting materials.
S3: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.06(s,1H),8.71(d,J=1.4Hz,1H),8.20(d,J=1.4Hz,1H),8.03(d,J=2.0Hz,1H),7.58(d,J=5.1Hz,1H),7.53–7.45(m,2H),7.36(t,J=4.4Hz,1H),7.08(ddd,J=12.4,7.9,1.3Hz,2H),6.88(t,J=3.8Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.13(t,J=5.9Hz,1H),4.34–4.24(m,3H),3.65(td,J=4.9,3.7Hz,2H),3.51(d,J=13.4Hz,1H),3.38(dtd,J=14.4,6.3,3.7Hz,1H),3.34–3.22(m,2H),3.20–3.10(m,2H),2.82(ddd,J=12.1,8.0,5.6Hz,2H),2.69(ddd,J=15.0,8.5,6.5Hz,1H),2.52(ddd,J=15.3,8.6,6.4Hz,1H),2.48–2.38(m,2H),2.43(s,3H),2.17–2.00(m,4H),1.85(ddt,J=11.4,7.9,5.7Hz,2H),1.69(dq,J=13.0,6.5Hz,1H),1.63–1.50(m,1H),1.53–1.45(m,1H),1.48–1.36(m,3H),1.39–1.29(m,1H).MS(ESI,m/z):874(M + +1).
EXAMPLE 19 Synthesis of Compounds S4 and S5
Synthetic method referring to example 17, compounds S4 and S5 can be prepared by simply replacing the corresponding starting materials.
S4: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.06(s,1H),8.70(d,J=1.6Hz,1H),8.15(d,J=1.4Hz,1H),7.95(d,J=2.0Hz,1H),7.59(d,J=4.9Hz,1H),7.52–7.43(m,2H),7.09(ddd,J=7.7,3.9,1.1Hz,2H),6.92(t,J=3.8Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.13(t,J=5.9Hz,1H),4.34–4.24(m,3H),3.65(td,J=4.9,3.7Hz,2H),3.51(dtd,J=14.5,6.3,3.8Hz,1H),3.29(dtd,J=14.5,6.4,3.8Hz,1H),3.01(ddd,J=11.9,8.0,5.7Hz,2H),2.69(ddd,J=15.0,8.5,6.5Hz,1H),2.58–2.46(m,3H),2.44(dt,J=11.9,6.3Hz,1H),2.40(s,2H),2.32(dt,J=11.9,6.3Hz,1H),2.17–2.07(m,1H),2.11–1.98(m,3H),1.81–1.68(m,3H),1.66–1.53(m,1H),1.50(dq,J=13.1,6.6Hz,1H),1.47–1.38(m,1H),1.40–1.33(m,1H),1.36–1.27(m,3H),1.30–1.16(m,1H).MS(ESI,m/z):832(M + +1).
S5: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.49(s,1H),8.70(d,J=1.6Hz,1H),8.23(s,1H),8.15(d,J=1.4Hz,1H),7.96(d,J=2.0Hz,1H),7.58(d,J=5.1Hz,1H),7.51(t,J=7.9Hz,1H),7.10(ddd,J=7.7,5.3,1.1Hz,2H),6.92(t,J=3.8Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.15(t,J=5.9Hz,1H),4.58(p,J=5.7Hz,1H),4.34–4.28(m,2H),3.65(td,J=4.9,3.7Hz,2H),3.42(dtd,J=14.5,6.3,3.8Hz,1H),3.31(dtd,J=14.5,6.3,3.7Hz,1H),3.05(ddd,J=11.9,8.0,5.6Hz,2H),2.70(ddd,J=15.2,8.6,6.3Hz,1H),2.58–2.48(m,3H),2.49–2.32(m,2H),2.40(s,3H),2.13–2.03(m,1H),2.02(ddd,J=11.4,8.0,5.6Hz,2H),1.94(ddt,J=11.3,8.6,6.2Hz,1H),1.79–1.65(m,3H),1.60(dp,J=13.3,6.6Hz,1H),1.54–1.40(m,2H),1.43–1.15(m,12H).MS(ESI,m/z):887(M + +1).
EXAMPLE 20 Synthesis of Compound S6
Synthetic method referring to example 16, compound S6 can be prepared by simply replacing the corresponding starting materials.
S6: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.06(s,1H),8.70(d,J=1.4Hz,1H),8.20(d,J=1.4Hz,1H),8.04(d,J=2.0Hz,1H),7.58(d,J=4.9Hz,1H),7.48(t,J=7.9Hz,1H),7.23(s,1H),7.10(dd,J=7.8,1.2Hz,1H),7.04(dd,J=7.9,1.3Hz,1H),6.92(t,J=3.8Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.12(t,J=5.9Hz,1H),4.44(p,J=5.6Hz,1H),4.34–4.28(m,2H),3.71(ddd,J=11.9,7.9,5.7Hz,2H),3.65(td,J=4.9,3.7Hz,2H),3.49–3.38(m,3H),3.27(dtd,J=14.5,6.3,3.7Hz,1H),2.69(ddd,J=15.0,8.5,6.5Hz,1H),2.52(ddd,J=15.1,8.6,6.4Hz,1H),2.43(s,2H),2.28(t,J=7.0Hz,2H),2.17–2.07(m,1H),2.10–1.99(m,3H),1.92(ddt,J=11.2,7.9,5.7Hz,2H),1.70(dq,J=13.0,6.6Hz,1H),1.58(dp,J=7.8,6.7Hz,3H),1.44(dp,J=13.7,6.8Hz,1H),1.33(dq,J=13.3,6.7Hz,1H).MS(ESI,m/z):845(M + +1).
EXAMPLE 21 Synthesis of Compound S7
Synthetic method referring to example 21, compound S7 can be prepared by simply replacing the corresponding starting materials.
S7: 1 H NMR(500MHz,Chloroform-d)δ9.89(s,1H),9.54(s,1H),8.70(d,J=1.5Hz,1H),8.20(d,J=1.5Hz,1H),7.93(d,J=2.0Hz,1H),7.73(dd,J=7.8,1.3Hz,1H),7.63–7.55(m,2H),7.34–7.25(m,2H),6.74(d,J=7.8Hz,1H),6.45(d,J=7.8Hz,1H),5.78(t,J=3.7Hz,1H),5.17(t,J=6.0Hz,1H),4.36–4.27(m,4H),4.11(dt,J=12.4,6.1Hz,1H),3.85–3.75(m,2H),3.79–3.69(m,2H),3.72–3.61(m,14H),3.65–3.60(m,1H),3.64–3.57(m,1H),3.60–3.47(m,1H),3.42(ddd,J=11.9,8.0,5.7Hz,2H),2.68(ddd,J=15.0,8.5,6.5Hz,1H),2.58(t,J=7.1Hz,2H),2.53(ddd,J=15.2,8.6,6.4Hz,1H),2.41(s,2H),2.19–2.08(m,1H),2.11–2.03(m,1H),2.02(ddd,J=11.3,8.0,5.6Hz,2H),1.89(ddt,J=11.3,8.1,5.7Hz,2H).MS(ESI,m/z):981(M + +1).
EXAMPLE 22 Synthesis of Compound S8
Synthetic method referring to example 21, compound S8 can be prepared by simply replacing the corresponding starting materials.
S8: 1 H NMR(500MHz,Chloroform-d)δ9.81(s,1H),9.06(s,1H),8.70(d,J=1.4Hz,1H),8.20(d,J=1.4Hz,1H),7.96–7.86(m,2H),7.61–7.50(m,2H),7.37(t,J=7.9Hz,1H),7.27(s,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),4.38(d,J=0.7Hz,2H),4.34–4.24(m,4H),3.65(td,J=4.9,3.7Hz,2H),3.53(ddd,J=11.9,8.0,5.7Hz,2H),3.44(ddd,J=11.9,8.0,5.7Hz,2H),2.70(ddd,J=15.2,8.6,6.3Hz,1H),2.56(ddd,J=15.2,8.6,6.4Hz,1H),2.41(s,3H),2.40(dt,J=12.3,6.1Hz,1H),2.35–2.24(m,2H),2.21(dt,J=14.2,7.1Hz,1H),2.01–1.85(m,3H),1.87–1.74(m,3H),1.60(dp,J=9.2,6.7Hz,3H),1.51–1.40(m,1H),1.43–1.20(m,6H).MS(ESI,m/z):868(M + +1).
EXAMPLE 23 Synthesis of Compounds S9 and S10
Synthetic method referring to example 16, compounds S9 and S10 can be prepared by simply replacing the corresponding starting materials.
S9: 1 H NMR(500MHz,Chloroform-d)δ9.81(s,1H),9.06(s,1H),8.70(d,J=1.4Hz,1H),8.20(d,J=1.4Hz,1H),8.04(d,J=1.8Hz,1H),7.66–7.55(m,3H),7.49(ddt,J=7.5,1.8,0.9Hz,1H),7.27(s,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),4.37(dd,J=13.5,1.1Hz,1H),4.34–4.26(m,3H),4.16–4.04(m,2H),3.65(td,J=4.8,3.7Hz,2H),3.58(ddd,J=12.1,8.0,5.7Hz,2H),3.44(ddd,J=11.9,7.9,5.7Hz,2H),2.67(ddd,J=15.2,8.7,6.3Hz,1H),2.52(ddd,J=15.2,8.6,6.3Hz,1H),2.45–2.16(m,8H),2.00(ddt,J=11.4,8.1,5.7Hz,2H),1.85(dddt,J=33.0,12.4,8.6,6.0Hz,3H),1.68–1.58(m,1H),1.61–1.51(m,2H),1.52–1.42(m,1H),1.45–1.32(m,1H),1.36–1.24(m,3H),1.28–1.20(m,2H).MS(ESI,m/z):868(M + +1).
S10: 1 H NMR(500MHz,Chloroform-d)δ9.81(s,1H),9.06(s,1H),8.70(d,J=1.4Hz,1H),8.20(d,J=1.4Hz,1H),7.93(d,J=2.0Hz,1H),7.71(s,1H),7.60–7.49(m,3H),7.26(dq,J=7.7,1.2Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),4.58(p,J=5.7Hz,1H),4.39–4.28(m,5H),3.83(ddd,J=11.9,8.1,5.7Hz,2H),3.65(td,J=4.9,3.7Hz,2H),3.44(ddd,J=12.1,8.1,5.7Hz,2H),2.66(ddd,J=15.0,8.5,6.4Hz,1H),2.60–2.43(m,2H),2.40(s,3H),2.44–2.27(m,3H),2.07–1.77(m,8H).MS(ESI,m/z):812(M + +1).
EXAMPLE 24 Synthesis of Compound S11
Synthetic method referring to example 16, compound S11 can be prepared by simply replacing the corresponding starting materials.
S11: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.06(s,1H),8.70(d,J=1.4Hz,1H),8.20(d,J=1.4Hz,1H),8.03(d,J=2.0Hz,1H),7.78(dd,J=7.9,1.3Hz,1H),7.56(d,J=4.9Hz,1H),7.51(t,J=7.6Hz,1H),7.44(dq,J=7.3,1.1Hz,1H),7.23(s,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.13(t,J=5.9Hz,1H),4.38–4.28(m,3H),3.68–3.57(m,4H),3.44(ddd,J=11.9,8.1,5.7Hz,2H),2.84(dtd,J=14.8,6.4,1.0Hz,1H),2.68(ddd,J=15.0,8.0,7.0Hz,1H),2.62–2.48(m,2H),2.42(s,2H),2.27(t,J=7.0Hz,2H),2.16–2.00(m,4H),1.92(ddt,J=11.4,8.1,5.7Hz,2H),1.74(dt,J=13.1,6.6Hz,1H),1.73–1.64(m,1H),1.61(p,J=6.9Hz,2H),1.51–1.34(m,3H).MS(ESI,m/z):830(M + +1).
EXAMPLE 25 Synthesis of Compound S12
Synthetic method referring to example 16, compound S12 can be prepared by simply replacing the corresponding starting materials.
S12: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.06(s,1H),8.80(dd,J=7.8,1.2Hz,1H),8.70(d,J=1.6Hz,1H),8.15(d,J=1.4Hz,1H),8.04(d,J=2.0Hz,1H),7.68(t,J=7.8Hz,1H),7.52(d,J=4.9Hz,1H),7.46(dd,J=7.9,1.1Hz,1H),7.35(s,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.20(t,J=5.9Hz,1H),4.35–4.27(m,3H),3.65(td,J=4.9,3.7Hz,2H),2.99(ddd,J=12.1,8.1,5.7Hz,2H),2.70(ddd,J=15.0,8.4,6.2Hz,1H),2.55(ddd,J=15.2,8.6,6.3Hz,1H),2.49–2.40(m,1H),2.32(s,3H),2.40–2.06(m,7H),1.90(ddt,J=11.4,8.1,5.7Hz,2H),1.79–1.55(m,6H),1.54–1.44(m,1H),1.48–1.34(m,2H).MS(ESI,m/z):845(M + +1).
EXAMPLE 26 Synthesis of Compound S13
Synthetic method referring to example 17, compound S13 can be prepared by simply replacing the corresponding starting materials.
S13: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.06(s,1H),8.70(d,J=1.6Hz,1H),8.15(d,J=1.4Hz,1H),7.92(d,J=2.0Hz,1H),7.56–7.44(m,4H),7.30(dd,J=7.9,1.3Hz,1H),7.17(dd,J=7.9,1.3Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),6.17(t,J=5.1Hz,1H),5.78(t,J=3.7Hz,1H),5.30(t,J=5.9Hz,1H),4.45(p,J=5.7Hz,1H),4.34–4.28(m,2H),4.20(dd,J=17.7,5.0Hz,1H),4.02(dd,J=17.6,5.1Hz,1H),3.65(td,J=4.9,3.7Hz,2H),3.05(td,J=6.1,4.4Hz,2H),2.91(ddd,J=12.1,8.0,5.7Hz,2H),2.69(ddd,J=14.9,8.4,6.4Hz,1H),2.61(ddd,J=15.4,8.6,6.6Hz,1H),2.50–2.34(m,7H),2.18–2.08(m,1H),2.11–2.03(m,1H),2.02(ddd,J=11.2,8.0,5.6Hz,2H),1.79(ddt,J=11.4,8.1,5.7Hz,2H),1.67(dq,J=12.8,6.4Hz,1H),1.56–1.28(m,5H).MS(ESI,m/z):874(M + +1).
EXAMPLE 27 Synthesis of Compound S14
Synthetic method referring to example 17, compound S14 can be prepared by simply replacing the corresponding starting materials.
S14: 1 H NMR(500MHz,Chloroform-d)δ9.89(s,1H),9.06(s,1H),8.70(d,J=1.6Hz,1H),8.15(d,J=1.4Hz,1H),8.03(d,J=2.0Hz,1H),7.64(dd,J=7.7,1.3Hz,1H),7.61–7.53(m,2H),7.46(s,1H),7.24(dd,J=7.7,1.3Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.14(t,J=5.9Hz,1H),4.34–4.28(m,2H),4.28–4.14(m,2H),4.08(dt,J=11.7,6.0Hz,1H),3.65(td,J=4.9,3.7Hz,2H),2.99(ddd,J=12.1,8.0,5.7Hz,2H),2.69(ddd,J=15.2,8.4,6.5Hz,1H),2.53(ddd,J=15.2,8.6,6.4Hz,1H),2.48–2.38(m,1H),2.42(s,3H),2.37–2.28(m,1H),2.23–2.00(m,6H),1.91–1.74(m,4H),1.57–1.45(m,1H),1.44–1.29(m,6H).MS(ESI,m/z):832(M + +1).
EXAMPLE 28 Synthesis of Compound S15
Synthetic method referring to example 16, compound S15 can be prepared by simply replacing the corresponding starting materials.
S15: 1 H NMR(500MHz,Chloroform-d)δ9.89(s,1H),9.06(s,1H),8.71(d,J=1.4Hz,1H),8.20(d,J=1.4Hz,1H),8.03(d,J=2.0Hz,1H),7.73(dd,J=7.9,1.3Hz,1H),7.64–7.54(m,2H),7.50(s,1H),7.43(t,J=4.4Hz,1H),7.33(dd,J=7.8,1.2Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.26(t,J=5.9Hz,1H),4.35–4.26(m,3H),4.17(dt,J=12.1,6.1Hz,1H),4.08(dt,J=11.9,6.1Hz,1H),3.65(td,J=4.9,3.7Hz,2H),3.50(d,J=13.2Hz,1H),3.19–3.01(m,3H),2.83(ddd,J=12.1,8.0,5.6Hz,2H),2.74–2.63(m,1H),2.57(ddd,J=15.2,8.0,7.1Hz,1H),2.44(s,3H),2.49–2.39(m,2H),2.16–2.01(m,4H),1.83(ddt,J=11.4,8.1,5.7Hz,2H),1.79–1.41(m,6H).MS(ESI,m/z):875(M + +1).
EXAMPLE 29 Synthesis of Compound S16
Synthetic method referring to example 17, compound S16 can be prepared by simply replacing the corresponding starting materials.
S16: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.12(s,1H),8.04(d,J=2.0Hz,1H),7.63–7.57(m,3H),7.48(t,J=7.9Hz,1H),7.37(s,1H),7.09(ddd,J=7.8,4.3,1.3Hz,2H),6.92(t,J=3.8Hz,1H),6.82–6.71(m,3H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.12(t,J=5.9Hz,1H),4.34–4.28(m,2H),3.65(td,J=4.8,3.7Hz,2H),3.41(dtd,J=14.5,6.2,3.7Hz,1H),3.28(dtd,J=14.5,6.3,3.7Hz,1H),3.24–3.15(m,4H),2.79–2.70(m,4H),2.73–2.64(m,1H),2.52(ddd,J=15.3,8.6,6.5Hz,1H),2.42(s,3H),2.47–2.38(m,1H),2.32(dt,J=12.0,6.4Hz,1H),2.17–2.01(m,2H),1.79–1.68(m,1H),1.66–1.52(m,2H),1.52–1.19(m,11H).MS(ESI,m/z):870(M + +1).
EXAMPLE 30 Synthesis of Compound S17
Synthetic method referring to example 16, compound S17 can be prepared by simply replacing the corresponding starting materials.
S17: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.12(s,1H),8.04(d,J=2.0Hz,1H),7.64–7.57(m,3H),7.48(t,J=7.9Hz,1H),7.40–7.31(m,2H),7.10(ddd,J=7.7,4.9,1.2Hz,2H),6.88(t,J=3.7Hz,1H),6.84–6.77(m,2H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.15(t,J=5.9Hz,1H),4.34–4.28(m,2H),3.68–3.57(m,3H),3.53–3.42(m,2H),3.37(t,J=5.3Hz,4H),3.26(dtd,J=14.3,6.3,4.4Hz,1H),3.22–3.10(m,2H),2.82–2.71(m,4H),2.69(ddd,J=15.2,8.4,6.5Hz,1H),2.52(ddd,J=15.2,8.6,6.5Hz,1H),2.42(s,3H),2.16–2.01(m,2H),1.69(dq,J=13.0,6.5Hz,1H),1.63–1.50(m,1H),1.53–1.41(m,2H),1.45–1.34(m,1H),1.38–1.28(m,1H).MS(ESI,m/z):885(M + +1).
EXAMPLE 31 Synthesis of Compound S18
Synthetic method referring to example 17, compound S18 can be prepared by simply replacing the corresponding starting materials.
S18: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.04(s,1H),7.94(d,J=2.0Hz,1H),7.54–7.45(m,2H),7.13–7.02(m,3H),6.95–6.88(m,2H),6.86(dt,J=8.4,1.0Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.09(t,J=5.9Hz,1H),4.35–4.28(m,3H),3.95(dd,J=13.6,1.1Hz,1H),3.83(s,3H),3.65(td,J=4.9,3.8Hz,2H),3.51(dtd,J=14.5,6.3,3.7Hz,1H),3.29(dtd,J=14.5,6.3,3.7Hz,1H),2.95–2.80(m,3H),2.74–2.63(m,2H),2.59(dt,J=12.0,6.4Hz,1H),2.57–2.46(m,2H),2.39(s,3H),2.17–2.01(m,2H),1.77–1.65(m,1H),1.64(dt,J=13.1,6.5Hz,1H),1.56(tt,J=13.0,6.5Hz,2H),1.45–1.28(m,2H).MS(ESI,m/z):829(M + +1).
EXAMPLE 32 Synthesis of Compound S19
Synthetic method referring to example 16, compound S19 can be prepared by simply replacing the corresponding starting materials.
S19: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.04(s,1H),8.03(d,J=2.0Hz,1H),7.59(d,J=4.9Hz,1H),7.50(t,J=7.8Hz,1H),7.32(t,J=4.3Hz,1H),7.23–7.12(m,3H),7.05(d,J=8.4Hz,1H),6.91–6.84(m,2H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.15(t,J=6.0Hz,1H),4.34–4.28(m,2H),3.89–3.82(m,1H),3.84(s,3H),3.65(td,J=4.9,3.8Hz,2H),3.60(dd,J=13.5,1.0Hz,1H),3.48–3.38(m,2H),3.32(dtd,J=14.5,6.4,3.8Hz,1H),3.29–3.19(m,2H),3.07(dtd,J=14.3,6.3,4.4Hz,1H),2.99(dd,J=5.6,4.9Hz,2H),2.85(ddd,J=15.4,5.7,4.8Hz,1H),2.76(dt,J=15.4,5.2Hz,1H),2.69(ddd,J=15.2,8.4,6.5Hz,1H),2.53(ddd,J=15.2,8.5,6.4Hz,1H),2.43(s,3H),2.16–2.02(m,2H),1.76–1.64(m,1H),1.63–1.28(m,5H).MS(ESI,m/z):886(M + +1).
EXAMPLE 33 Synthesis of Compound S20
Synthetic method referring to example 17, compound S20 can be prepared by replacing the corresponding starting materials.
S20: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.49(s,1H),7.62–7.55(m,2H),7.48(t,J=7.8Hz,1H),7.46–7.35(m,2H),7.33(t,J=2.2Hz,1H),7.32–7.24(m,1H),7.11(dd,J=7.8,1.1Hz,1H),7.10–7.01(m,2H),6.92(t,J=3.7Hz,1H),6.85(dt,J=8.4,1.0Hz,1H),5.65(d,J=7.0Hz,1H),5.52(d,J=7.0Hz,1H),5.13(t,J=5.9Hz,1H),4.22–4.15(m,1H),3.83(s,3H),3.77(dd,J=13.6,1.1Hz,1H),3.48(dtd,J=14.5,6.3,3.7Hz,1H),3.32(dtd,J=14.5,6.3,3.7Hz,1H),2.91–2.81(m,3H),2.77–2.59(m,3H),2.57–2.47(m,1H),2.51–2.42(m,1H),2.17–2.02(m,2H),1.76–1.49(m,4H),1.48–1.30(m,2H).MS(ESI,m/z):775(M + +1).
EXAMPLE 34 Synthesis of Compound S21
Synthetic method referring to example 16, compound S21 can be prepared by simply replacing the corresponding starting materials.
S21: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.62(s,1H),7.62–7.55(m,2H),7.46(t,J=7.9Hz,1H),7.46–7.35(m,2H),7.36–7.25(m,3H),7.13–7.02(m,3H),6.88(t,J=3.7Hz,1H),6.81(dt,J=8.4,1.0Hz,1H),5.65(d,J=7.1Hz,1H),5.53(d,J=7.0Hz,1H),5.04(t,J=5.9Hz,1H),3.88(dd,J=13.5,0.9Hz,1H),3.82(s,3H),3.72(dd,J=13.6,0.9Hz,1H),3.60(dtd,J=14.5,6.3,3.8Hz,1H),3.41(d,J=13.2Hz,1H),3.34–3.21(m,2H),3.24–3.14(m,1H),3.10(dtd,J=14.3,6.3,4.4Hz,1H),2.99(t,J=5.3Hz,2H),2.90–2.81(m,1H),2.73–2.60(m,2H),2.48(ddd,J=15.1,8.7,6.3Hz,1H),2.21(ddt,J=11.2,8.6,6.1Hz,1H),2.05(ddt,J=11.2,8.6,6.0Hz,1H),1.69(dq,J=13.0,6.5Hz,1H),1.63–1.51(m,1H),1.53–1.45(m,1H),1.49–1.42(m,1H),1.46–1.28(m,2H).MS(ESI,m/z):832(M + +1).
EXAMPLE 35 Synthesis of Compound S22
Synthetic method referring to example 16, compound S22 can be prepared by simply replacing the corresponding starting materials.
S22: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.75(d,J=2.2Hz,1H),8.70(d,J=1.6Hz,1H),8.24–8.14(m,3H),8.06(s,1H),7.99(dd,J=8.6,2.0Hz,1H),7.53(t,J=7.8Hz,1H),7.36(t,J=4.4Hz,1H),7.30–7.23(m,2H),7.10(dd,J=7.8,1.2Hz,1H),6.88(t,J=3.7Hz,1H),5.60(t,J=3.7Hz,1H),5.13(t,J=5.9Hz,1H),4.37–4.27(m,3H),3.65(ddd,J=5.2,4.6,3.8Hz,2H),3.60–3.47(m,2H),3.25(dtd,J=14.5,6.3,3.8Hz,1H),3.16(d,J=13.2Hz,1H),3.08(td,J=6.3,4.4Hz,2H),2.83(ddd,J=12.1,8.0,5.7Hz,2H),2.69(ddd,J=15.2,8.5,6.5Hz,1H),2.57–2.47(m,1H),2.44(ddd,J=12.1,8.1,5.7Hz,2H),2.39(s,3H),2.17–2.01(m,4H),1.84(ddt,J=11.4,8.1,5.7Hz,2H),1.76–1.64(m,1H),1.63–1.42(m,3H),1.42–1.28(m,2H).MS(ESI,m/z):841(M + +1).
EXAMPLE 36 Synthesis of Compound S23
Synthetic method referring to example 17, compound S23 can be prepared by simply replacing the corresponding starting materials.
S23: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),9.74(d,J=1.8Hz,1H),8.70(d,J=1.6Hz,1H),8.24–8.17(m,3H),8.08–8.01(m,2H),7.50(t,J=7.9Hz,1H),7.26(s,1H),7.20(ddd,J=16.1,7.9,1.3Hz,2H),6.92(t,J=3.8Hz,1H),5.60(t,J=3.7Hz,1H),5.16(t,J=5.9Hz,1H),4.32(td,J=4.9,0.8Hz,2H),4.27(p,J=5.7Hz,1H),3.65(ddd,J=5.2,4.6,3.8Hz,2H),3.46(dtd,J=14.5,6.3,3.8Hz,1H),3.23(dtd,J=14.5,6.3,3.8Hz,1H),3.01(ddd,J=11.9,8.0,5.6Hz,2H),2.68(ddd,J=15.0,8.6,6.3Hz,1H),2.52(ddd,J=15.2,8.8,6.4Hz,1H),2.43(dt,J=11.9,6.3Hz,1H),2.39(s,3H),2.32(dt,J=11.9,6.3Hz,1H),2.27–2.17(m,3H),2.12–2.01(m,3H),1.85–1.78(m,1H),1.81–1.75(m,1H),1.78–1.68(m,1H),1.67–1.55(m,1H),1.58–1.27(m,5H),1.30–1.16(m,1H).MS(ESI,m/z):798(M + +1).
EXAMPLE 37 Synthesis of Compound S24
Synthetic method referring to example 17, compound S24 can be prepared by simply replacing the corresponding starting materials.
S24: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),7.69(t,J=2.1Hz,1H),7.62(ddd,J=8.1,5.0,1.1Hz,1H),7.54–7.45(m,2H),7.48–7.37(m,2H),7.27(ddd,J=8.3,6.4,2.4Hz,1H),7.10(ddd,J=7.7,4.5,1.2Hz,2H),7.04(d,J=8.4Hz,1H),6.98–6.89(m,2H),6.86(dt,J=8.6,1.0Hz,1H),6.08(d,J=7.0Hz,1H),5.63(d,J=7.1Hz,1H),5.17(t,J=5.9Hz,1H),4.19(dd,J=13.6,0.9Hz,1H),3.86(s,3H),3.77(dd,J=13.6,1.1Hz,1H),3.52(dtd,J=14.5,6.3,3.7Hz,1H),3.33(dtd,J=14.5,6.3,3.7Hz,1H),2.91–2.82(m,2H),2.73–2.43(m,6H),2.22(ddt,J=11.3,8.6,6.1Hz,1H),2.08(ddt,J=11.3,8.6,6.2Hz,1H),1.71(ddq,J=25.9,13.0,6.6Hz,2H),1.66–1.54(m,1H),1.52–1.35(m,2H),1.38–1.31(m,1H),1.34–1.20(m,4H).MS(ESI,m/z):786(M + +1).
EXAMPLE 38 Synthesis of Compound S25
Synthetic method referring to example 17, compound S25 can be prepared by simply replacing the corresponding starting materials.
S25: 1 H NMR(500MHz,Chloroform-d)δ9.92(s,1H),7.79–7.70(m,2H),7.62(ddd,J=8.3,5.1,1.3Hz,1H),7.54–7.43(m,2H),7.46–7.35(m,3H),7.28(ddd,J=8.3,6.9,2.2Hz,1H),7.21(dd,J=7.9,1.3Hz,1H),7.09–7.00(m,2H),6.99(t,J=3.7Hz,1H),6.81(dt,J=8.4,1.0Hz,1H),6.08(d,J=7.0Hz,1H),5.63(d,J=7.1Hz,1H),5.14(t,J=5.9Hz,1H),3.81(dd,J=13.6,1.1Hz,1H),3.80(s,3H),3.52(dd,J=13.6,0.9Hz,1H),3.38(dtd,J=14.3,6.1,3.7Hz,1H),3.33–3.19(m,3H),3.09(dtd,J=14.4,6.2,4.3Hz,1H),3.03–2.94(m,3H),2.82–2.68(m,2H),2.63(dt,J=15.4,5.3Hz,1H),2.53(ddd,J=15.2,8.6,6.3Hz,1H),2.10(ddt,J=11.3,8.8,6.1Hz,1H),1.94(ddt,J=11.3,8.8,6.1Hz,1H),1.72–1.41(m,4H).MS(ESI,m/z):801(M + +1).
EXAMPLE 39 Synthesis of Compound S26
Synthetic method referring to example 16, compound S26 can be prepared by simply replacing the corresponding starting materials.
S26: 1 H NMR(500MHz,Chloroform-d)δ9.32(s,1H),8.74(s,1H),7.76(dd,J=5.0,2.1Hz,1H),7.66(d,J=9.0Hz,1H),7.52(dddd,J=8.0,5.0,2.1,1.2Hz,1H),7.51–7.44(m,2H),7.46–7.34(m,3H),7.35–7.28(m,2H),7.29–7.22(m,1H),7.18(d,J=8.6Hz,1H),7.13(s,1H),7.05(d,J=8.4Hz,1H),6.84(dt,J=8.4,1.0Hz,1H),6.58(d,J=7.9Hz,1H),6.39(d,J=7.9Hz,1H),5.11(dqt,J=8.1,6.0,1.0Hz,1H),4.66(d,J=8.8Hz,1H),4.51(dd,J=5.9,4.9Hz,1H),4.36(ttd,J=5.8,4.7,3.3Hz,1H),3.86(dd,J=13.6,1.1Hz,1H),3.84(s,3H),3.68–3.58(m,2H),3.56(d,J=5.7Hz,1H),3.46–3.38(m,2H),3.31(dtd,J=14.3,6.3,4.4Hz,1H),3.19(d,J=13.2Hz,1H),3.09(dtd,J=14.3,6.3,4.4Hz,1H),3.03–2.94(m,2H),2.85–2.76(m,1H),2.69(dt,J=15.6,5.3Hz,1H),2.52(s,3H),2.39–2.24(m,2H),2.18(ddd,J=13.2,5.9,4.8Hz,1H),2.06(ddd,J=13.2,5.9,4.9Hz,1H),1.87(tdd,J=13.3,7.1,6.2Hz,1H),1.72(tdd,J=13.4,7.0,6.3Hz,1H),1.53(d,J=6.2Hz,3H),0.96(s,9H).MS(ESI,m/z):1003(M + +1).
EXAMPLE 40 Synthesis of Compound S27
Synthetic method referring to example 17, compound S27 can be prepared by simply replacing the corresponding starting materials.
S27: 1 H NMR(500MHz,Chloroform-d)δ9.31(s,1H),8.74(s,1H),7.76(dd,J=5.0,2.1Hz,1H),7.58(d,J=9.0Hz,1H),7.56–7.46(m,3H),7.46–7.34(m,2H),7.38–7.31(m,2H),7.25(ddd,J=7.9,7.0,1.8Hz,1H),7.18(t,J=4.3Hz,2H),7.04(d,J=8.4Hz,1H),6.82(dt,J=8.4,1.0Hz,1H),6.58(d,J=7.9Hz,1H),6.39(d,J=7.9Hz,1H),5.11(dqt,J=8.1,6.1,1.0Hz,1H),4.58(d,J=9.0Hz,1H),4.52(dd,J=5.9,4.9Hz,1H),4.41–4.32(m,1H),4.21(dd,J=13.5,0.9Hz,1H),3.85–3.76(m,5H),3.64(dd,J=10.8,4.4Hz,1H),3.59(d,J=5.7Hz,1H),3.43(dd,J=10.9,3.4Hz,1H),2.91–2.82(m,2H),2.80(ddd,J=15.4,5.9,4.8Hz,1H),2.71–2.59(m,2H),2.49(s,3H),2.49(dt,J=11.9,6.4Hz,2H),2.33–2.19(m,2H),2.07(ddd,J=13.2,5.9,4.9Hz,1H),1.87(ddd,J=13.4,6.0,4.9Hz,1H),1.69–1.46(m,7H),1.39–1.29(m,1H),1.32–1.20(m,3H),0.97(s,9H).MS(ESI,m/z):988(M + +1).
EXAMPLE 41 Synthesis of Compound S28
Synthetic method referring to example 17, compound S28 can be prepared by simply replacing the corresponding starting materials.
S28: 1 H NMR(500MHz,Chloroform-d)δ9.51(s,1H),8.73(s,1H),8.11(d,J=2.0Hz,1H),7.87(d,J=5.1Hz,1H),7.58(d,J=9.0Hz,1H),7.44–7.37(m,2H),7.36–7.29(m,2H),7.22–7.15(m,2H),7.04(d,J=8.4Hz,1H),6.88(dt,J=8.4,1.0Hz,1H),6.74(d,J=7.9Hz,1H),6.45(d,J=7.9Hz,1H),5.78(t,J=3.7Hz,1H),5.11(dqt,J=8.1,6.1,1.0Hz,1H),4.66(d,J=9.0Hz,1H),4.46–4.37(m,1H),4.34–4.27(m,3H),4.21(dd,J=5.8,5.0Hz,1H),3.84(s,2H),3.72(dd,J=13.6,1.1Hz,1H),3.68–3.61(m,3H),3.43(dd,J=10.9,3.4Hz,1H),2.96–2.82(m,2H),2.81–2.72(m,2H),2.74–2.60(m,2H),2.58–2.49(m,1H),2.54(s,3H),2.39(s,2H),2.22(td,J=7.1,1.8Hz,2H),2.05–1.91(m,2H),1.74(dh,J=13.0,6.5Hz,1H),1.64(dq,J=12.9,6.9Hz,1H),1.61–1.48(m,5H),1.43–1.18(m,6H),0.97(s,9H).MS(ESI,m/z):1042(M + +1).
EXAMPLE 42 test of the Compounds of the invention for HPK1 kinase Activity
HPK1 kinase domain (1-307 aa) was solubilized in the kinase buffer (20mM HEPES pH7.5,10mM MgCl) 2 1mM EGTA,0.5mM TCEP,0.01%Brij-35,0.05% BSA) was added to a 96-well plate at a final concentration of 20nM, then a gradient of a test compound of the present invention (10 concentration points were set for each compound), HPK1 kinase was pre-incubated with the compound of the present invention for 30min, then 20. Mu.L of a substrate solution (SLP 76-SH at a final concentration of 0.5 mg/mL) was added to each well 2 Domain and 10 μm ATP) initiates the enzymatic reaction. Incubation was performed for 1h at room temperature, and the inhibition of HPK1 kinase activity by the compounds of the invention was then determined at each concentration according to the instructions of Luminescent Kinase Assay Kit (Beyotime Biotechnology Company). Calculation of the inhibitory Activity of the Compounds of the invention against HPK1 kinase IC using GraphPad fitting 50 The values were determined by merck, compound A, B and C as positive controls. The experimental results are shown in table 1.
TABLE 1 kinase inhibitory Activity of the inventive Compounds against HPK1 protein (IC 50 nM)
Numbering of compounds | Enzyme inhibition Activity | Numbering of compounds | Enzyme inhibition Activity |
S1 | 20.5 | S17 | 32.5 |
S2 | 22.3 | S18 | 25.3 |
S3 | 9.9 | S19 | 37.3 |
S4 | 9.5 | S20 | 7.3 |
S5 | 9.6 | S21 | 8.9 |
S6 | 30.5 | S22 | 32.6 |
S7 | 40.8 | S23 | 37.5 |
S8 | 28.3 | S24 | 8.9 |
S9 | 29.6 | S25 | 7.6 |
S10 | 28.7 | S26 | 22.3 |
S11 | 28.3 | S27 | 26.2 |
S12 | 10.2 | S28 | 19.6 |
S13 | 9.9 | A | 7.7 |
S14 | 10.5 | B | 21.8 |
S15 | 12.3 | C | 36.8 |
S16 | 33.2 |
Compared with the positive control compounds A and B, the compound provided by the invention has basically equivalent positive control activity, which shows that the compound provided by the invention basically maintains the HPK1 inhibitory activity and has better combination with HPK1 protein.
EXAMPLE 43 assay of the degradation Activity of some of the compounds of the invention on HPK1 protein
(1) Collecting cells: jurkat cells were cultured for 12h with adherence, and a portion of the compounds of the invention (0.1. Mu.M, 1. Mu.M, 10. Mu.M) was incubated with the cells for 12h.
(2) Extracting protein: the original culture medium is discarded, the cells are washed three times by precooled PBS, a proper amount of lysate is added, the mixture is evenly mixed and placed on ice for being cracked for 30min, the mixture is centrifuged for 5min at 12000rpm at 4 ℃, and the supernatant after centrifugation is transferred into a new centrifuge tube for preparation for quantification.
(3) Protein quantification: protein is quantified by adopting BCA, and BCA working solution is obtained after the solution A and the solution B are evenly mixed according to the proportion of 50:1. 100. Mu.L of BCA working solution, 9. Mu.L of triple distilled water and 1. Mu.L of protein sample were added to a 96-well plate, and incubated at 37℃for 30min after mixing, absorbance was measured with a full-wavelength microplate reader, and protein concentration was calculated from a standard curve. The quantified protein was mixed with a 5×loading buffer at a ratio of 4:1, denatured in boiling water for 8min, placed on ice, cooled and stored at-20℃until use.
(4) Preparing SDS-PAGE gel, concentrating gel at 90V, separating gel at 120V and at 4deg.C, transferring membrane at 100V for 1 hr, immediately placing protein membrane into 5% BSA solution, slowly shaking on shaking table, and sealing at room temperature for 1 hr.
(5) Referring to the instructions of HPK1 anti-body (4472 SCST), GLK (D1L 4G) Rabbit mAb (92427 SCST), rabbit mAb (92711 TCST), β -actin Mouse Monoclonal Antibody (BE 0021 easybio), the primary Antibody was diluted in the appropriate proportions, incubated overnight with slow shaking at 4℃and washed 3 more times with PBST for 10 min/time.
(6) According to the primary antibody selection of the Goat Anti-Rabbit IgG (H & L) -HRP Conj ugated (BE 0101 easy) or Goat Anti-Mouse IgG (H & L) -HRP Conj ugated (BE 0102 easy), reference to the second antibody instructions, the second antibody was diluted in the appropriate proportion, slowly shaken at room temperature for incubation for 1H, washed 3 times with PBST, 10 min/time.
(7) ECL luminescence was added, the results were observed by a developing instrument, western results were quantified using Image J software, and degradation rates (HPK 1 and GLK) were calculated by comparison with a control group without compound. The experimental results are shown in table 2.
TABLE 2 kinase inhibitory Activity of the inventive Compounds against HPK1 protein (IC 50 nM)
Experimental results show that the compound has good degradation activity on HPK1 protein and is dose-dependent, and the degradation rate of the compound on GLK protein is low at 1.0 mu M, which indicates that the compound can efficiently and selectively reduce HPK1 protein.
Example 44T cytokine Release assay
HPK1 kinase inhibits T cell effector cytokine release, and thus it was examined whether the compounds of the present invention could enhance T cell cytokine release capacity by ELISA method. Human PBMC cells were thawed and suspended in RPMI 1640 (Gibco) medium containing 10% bovine placental serum and cells were seeded in 96-well plates (1X 10) 5 /hole). The compound of the invention was added in a gradient dilution to a 96-well plate at 37℃with 5% CO 2 Incubate in incubator for 1h. PBMCs cells were activated by addition of 100. Mu.Lof anti-CD3/CD28 antibody (final concentration 1. Mu.g/mL) and then incubated at 37℃with 5% CO 2 The supernatant was diluted with 8-fold PBS and 100. Mu.L of the diluted supernatant was used to measure the release of cytokine IL-2 at each concentration of the compounds of the invention using a human IL-2 ELISA kit (4 abio). Calculation of EC of the compounds of the invention using GraphPad fitting 50 Values. The experimental results are shown in table 3.
TABLE 3 results of assays for the IL-2 cytokine Activity of the inventive compounds to stimulate PBMC release
Numbering of compounds | EC 50 (nM) |
S13 | 32nM |
S20 | 25nM |
A | 140nM |
The compounds S13 and S20 of the invention are capable of significantly enhancing the release of IL-2 by PBMC cells and are superior to the positive control compound A. This demonstrates that the compounds of the invention are capable of enhancing T cell effector cytokine release by degrading the HPK1 protein, thereby restoring or enhancing an anti-tumor immune response.
Claims (6)
1. A compound represented by formula I or a pharmaceutically acceptable salt thereof,
in formula I:
R 1 hydrogen, halogen or cyano;
R 2 is that
R 3 Is hydrogen or amino;
q is N or C;
a is Terminal represents an association with NH, terminal represents an association with L;
b isY is hydrogen, deuterium, fluorine or chlorine; w is CH 2 Or carbonyl; g is hydrogen or methyl;
z is hydrogen or methyl;
l is Terminal represents a bond to A, "- -" terminal represents a bond to B;
m is an integer between 0 and 5, n is an integer between 0 and 10, and o is an integer between 1 and 5;
x is C, O, NH, The terminal is attached to L and the "- -" terminal is attached to B.
2. A compound or pharmaceutically acceptable salt thereof according to claim 1,
b is
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula I has the formula:
4. the compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula I is selected from the group consisting of compounds of any one of the following structures:
5. use of a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of diseases which are associated with HPK1 kinase.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or adjuvant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211448593.9A CN115873018B (en) | 2022-11-18 | 2022-11-18 | Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211448593.9A CN115873018B (en) | 2022-11-18 | 2022-11-18 | Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115873018A CN115873018A (en) | 2023-03-31 |
CN115873018B true CN115873018B (en) | 2024-03-15 |
Family
ID=85760270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211448593.9A Active CN115873018B (en) | 2022-11-18 | 2022-11-18 | Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115873018B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009145899A1 (en) * | 2008-05-30 | 2009-12-03 | Celgene Corporation | 5-substituted isoindoline compounds |
WO2019079357A1 (en) * | 2017-10-17 | 2019-04-25 | Silverback Therapeutics, Inc. | Tnik modulators, conjugates, and uses thereof |
WO2019195609A2 (en) * | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
WO2021051034A1 (en) * | 2019-09-13 | 2021-03-18 | Biotheryx, Inc. | Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
WO2021198966A1 (en) * | 2020-03-31 | 2021-10-07 | Orum Therapeutics, Inc. | Conjugates |
WO2022173032A1 (en) * | 2021-02-15 | 2022-08-18 | アステラス製薬株式会社 | Quinazoline compound for inducing degradation of g12d-mutation kras protein |
-
2022
- 2022-11-18 CN CN202211448593.9A patent/CN115873018B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009145899A1 (en) * | 2008-05-30 | 2009-12-03 | Celgene Corporation | 5-substituted isoindoline compounds |
WO2019079357A1 (en) * | 2017-10-17 | 2019-04-25 | Silverback Therapeutics, Inc. | Tnik modulators, conjugates, and uses thereof |
WO2019195609A2 (en) * | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
WO2021051034A1 (en) * | 2019-09-13 | 2021-03-18 | Biotheryx, Inc. | Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
WO2021198966A1 (en) * | 2020-03-31 | 2021-10-07 | Orum Therapeutics, Inc. | Conjugates |
WO2022173032A1 (en) * | 2021-02-15 | 2022-08-18 | アステラス製薬株式会社 | Quinazoline compound for inducing degradation of g12d-mutation kras protein |
Also Published As
Publication number | Publication date |
---|---|
CN115873018A (en) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230143751A1 (en) | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | |
WO2017076346A1 (en) | 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist | |
CN110092745B (en) | Compound containing aromatic ring and application thereof | |
JP2020527577A (en) | TLR7 / 8 antagonists and their use | |
WO2021252822A1 (en) | Heteroalkyl dihydroquinoline sulfonamide compounds | |
CN111171049B (en) | Tyrosine kinase inhibitors and uses thereof | |
US20230159529A1 (en) | Aromatic compound and application thereof in antitumor drug | |
JP2016169161A (en) | Novel imidazo pyridine compound | |
EP3500566A1 (en) | Spirocyclic containing compounds and pharmaceutical uses thereof | |
CN113024544B (en) | Cyano-containing heterocyclic compound and application thereof | |
CN109568321B (en) | ROR gamma modulators | |
CN110092740B (en) | Fused ring compound and application thereof | |
CN115353508B (en) | 5-pyridine-1H-indazole compound, pharmaceutical composition and application | |
CA3037971A1 (en) | New benzimidazoles derivatives as tec kinases family inhibitors | |
CN111635373B (en) | Polycyclic sulfonamide ROR gamma modulators | |
CN111971278A (en) | Quinoline compounds as IRAK inhibitors and uses thereof | |
WO2021129841A1 (en) | Compound used as ret kinase inhibitor and application thereof | |
CN115873018B (en) | Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof | |
JP7329052B2 (en) | Fluorine-containing substituted benzothiophene compounds and pharmaceutical compositions and applications thereof | |
CN117337290A (en) | Tri-ring ubiquitin-specific protease 1 inhibitors and uses thereof | |
CN111349077B (en) | Pyridazine derivative and preparation method and medical application thereof | |
CN111747927A (en) | Compounds as immunomodulators and uses thereof | |
EP3677581A1 (en) | Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof | |
CN115572294B (en) | Deuterated aza-indole dipyrazole compound, pharmaceutical composition and application | |
CN110092799B (en) | Cyclic compound, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |